多发性骨髓瘤及其前体状态的当前和未来成像方式。
Current and future imaging modalities for multiple myeloma and its precursor states.
机构信息
Multiple Myeloma Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Leuk Lymphoma. 2011 Sep;52(9):1630-40. doi: 10.3109/10428194.2011.573036. Epub 2011 Jun 8.
Abstract
Traditionally, the skeletal survey has been the standard modality for the detection of osteolytic bone disease in multiple myeloma. In addition to its poor sensitivity for the detection of osteolytic lesions, this modality is not able to identify extramedullary lesions and focal bone marrow involvement, nor measure response to therapy. The application of novel imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI), and molecular imaging such as fluorine-18 fluorodeoxyglucose positron emission tomography CT ((18)F-FDG PET/CT) and fluorine-18 sodium fluoride positron emission tomography CT ((18)F-NaF PET/CT) has the potential to overcome these limitations as well as provide prognostic information in precursor states and multiple myeloma. Also promising is the use of dynamic contrast enhanced magnetic resonance imaging (DCE MRI) to measure vascular permeability, an important feature of myelomagenesis. This review summarizes the current status and possible future role of novel imaging modalities in multiple myeloma and its precursor states.
摘要
传统上，骨骼扫描一直是多发性骨髓瘤溶骨性骨病检测的标准方式。除了对溶骨性病变的检测灵敏度较差外，这种方式还无法识别骨髓外病变和局灶性骨髓受累，也无法衡量治疗反应。新型成像技术的应用，如计算机断层扫描（CT）、磁共振成像（MRI）以及氟-18 氟代脱氧葡萄糖正电子发射断层扫描 CT（(18)F-FDG PET/CT）和氟-18 氟化钠正电子发射断层扫描 CT（(18)F-NaF PET/CT）等分子成像技术，具有克服这些局限性的潜力，并为前驱状态和多发性骨髓瘤提供预后信息。使用动态对比增强磁共振成像（DCE MRI）来测量血管通透性也是一种很有前途的方法，血管通透性是骨髓瘤发生的一个重要特征。本文综述了新型成像方式在多发性骨髓瘤及其前驱状态中的现状和可能的未来作用。
相似文献
1
Current and future imaging modalities for multiple myeloma and its precursor states.多发性骨髓瘤及其前体状态的当前和未来成像方式。
Leuk Lymphoma. 2011 Sep;52(9):1630-40. doi: 10.3109/10428194.2011.573036. Epub 2011 Jun 8.
2
¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.¹⁸F-FDG PET/CT：多发性骨髓瘤及相关疾病的诊断和预后特征综述
Clin Exp Med. 2015 Feb;15(1):1-18. doi: 10.1007/s10238-014-0308-3. Epub 2014 Sep 14.
3
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.多发性骨髓瘤及其前驱疾病中的骨髓异常和早期骨病变：一项使用功能和形态学成像的前瞻性研究
Leuk Lymphoma. 2016 May;57(5):1114-21. doi: 10.3109/10428194.2015.1090572. Epub 2016 Apr 7.
4
PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.正电子发射断层显像用于多发性骨髓瘤患者的初始分期和治疗评估
Int J Mol Sci. 2017 Feb 18;18(2):445. doi: 10.3390/ijms18020445.
5
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
6
[Imaging in smoldering (asymptomatic) multiple myeloma. Past, present and future].[冒烟型（无症状）多发性骨髓瘤的影像学：过去、现在与未来]
Radiologe. 2014 Jun;54(6):572, 574-81. doi: 10.1007/s00117-014-2694-7.
7
Molecular imaging in myeloma precursor disease.骨髓瘤前期疾病的分子成像。
Semin Hematol. 2011 Jan;48(1):22-31. doi: 10.1053/j.seminhematol.2010.11.006.
8
DCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET/MRI imaging approach.DCE-MRI 用于区分所有单克隆浆细胞疾病阶段，并与基于扩散加权 MRI/PET 的生物标志物在混合式同步全身 2-[18F]FDG-PET/MRI 成像方法中的相关性。
Cancer Imaging. 2024 Jul 11;24(1):93. doi: 10.1186/s40644-024-00740-5.
9
[Imaging techniques in multiple myeloma].[多发性骨髓瘤的影像学技术]
Nihon Rinsho. 2007 Dec;65(12):2261-7.
10
Imaging of Multiple Myeloma.多发性骨髓瘤的影像学检查
Rofo. 2019 Sep;191(9):805-816. doi: 10.1055/a-0864-2084. Epub 2019 Jun 11.
引用本文的文献
1
Comparative Study of Metabolic Tumor Volume in Multiple Myeloma and Related Plasma Cell Dyscrasias: 11C-Acetate PET vs. 18F-FDG PET.多发性骨髓瘤及相关浆细胞异常增生症中代谢肿瘤体积的比较研究：11C-乙酸盐PET与18F-FDG PET对比
Cureus. 2024 Oct 16;16(10):e71605. doi: 10.7759/cureus.71605. eCollection 2024 Oct.
2
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.新型亚型选择性组蛋白去乙酰化酶抑制剂西达本胺治疗骨髓瘤相关骨病的疗效。
Haematologica. 2018 Aug;103(8):1369-1379. doi: 10.3324/haematol.2017.181172. Epub 2018 May 17.
3
Quantitative analysis of F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.F-NaF动态PET/CT的定量分析无法区分多发性骨髓瘤中的恶性与良性病变。
Am J Nucl Med Mol Imaging. 2017 Sep 1;7(4):148-156. eCollection 2017.
4
An Evidence-Based Approach to Myeloma Bone Disease.骨髓瘤骨病的循证治疗方法
Curr Hematol Malig Rep. 2017 Apr;12(2):109-118. doi: 10.1007/s11899-017-0370-5.
5
Plumbagin inhibits cell proliferation and promotes apoptosis in multiple myeloma cells through inhibition of the PI3K/Akt-mTOR pathway.白花丹醌通过抑制PI3K/Akt-mTOR信号通路抑制多发性骨髓瘤细胞的增殖并促进其凋亡。
Oncol Lett. 2016 Nov;12(5):3614-3618. doi: 10.3892/ol.2016.5048. Epub 2016 Aug 26.
6
Treatment response evaluation with F-FDG PET/CT and F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.使用F-FDG PET/CT和F-NaF PET/CT对接受大剂量化疗和自体干细胞移植的多发性骨髓瘤患者进行治疗反应评估。
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):50-62. doi: 10.1007/s00259-016-3502-6. Epub 2016 Aug 29.
7
[Hemato-oncological imaging : Importance of hybrid procedures].[血液肿瘤影像学：混合检查方法的重要性]
Radiologe. 2016 Jul;56(7):597-604. doi: 10.1007/s00117-016-0126-6.
8
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.多发性骨髓瘤患者的溶骨性病变、细胞遗传学特征以及细胞因子和趋化因子的骨髓水平：趋化因子（C-C 基序）配体 20 的作用。
Leukemia. 2016 Feb;30(2):409-16. doi: 10.1038/leu.2015.259. Epub 2015 Sep 30.
9
Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden.利用全身扩散加权成像评估骨髓瘤骨病：按区域与X线骨骼检查对比及与疾病负担实验室评估的关系
Clin Radiol. 2015 Jun;70(6):614-21. doi: 10.1016/j.crad.2015.02.013. Epub 2015 Mar 19.
10
Diagnostic and Prognostic Implications of Spine Magnetic Resonance Imaging at Diagnosis in Patients with Multiple Myeloma.脊柱磁共振成像在多发性骨髓瘤患者诊断时的诊断及预后意义
Cancer Res Treat. 2015 Jul;47(3):465-72. doi: 10.4143/crt.2014.010. Epub 2014 Nov 3.
本文引用的文献
1
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.意义未明的单克隆丙种球蛋白血症（MGUS）和冒烟型（无症状）多发性骨髓瘤：IMWG 共识观点——进展风险因素以及监测和管理指南。
Leukemia. 2010 Jun;24(6):1121-7. doi: 10.1038/leu.2010.60. Epub 2010 Apr 22.
2
The role of whole-body imaging in the diagnosis, staging, and follow-up of multiple myeloma.全身成像在多发性骨髓瘤的诊断、分期及随访中的作用。
Semin Musculoskelet Radiol. 2010 Mar;14(1):37-46. doi: 10.1055/s-0030-1248705. Epub 2010 Mar 12.
3
Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging.全身动态对比增强磁共振成像在多发性骨髓瘤治疗反应评估中的应用。
Radiology. 2010 Feb;254(2):521-31. doi: 10.1148/radiol.09090629.
4
The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi.近期诊断为多发性骨髓瘤患者 F-18 氟脱氧葡萄糖骨髓摄取的预后价值：与 Tc-99m sestamibi 的对比研究。
Clin Nucl Med. 2010 Jan;35(1):1-5. doi: 10.1097/RLU.0b013e3181c3619c.
5
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.18F-氟脱氧葡萄糖正电子发射断层扫描在多发性骨髓瘤的其他成像技术及预后因素背景下的应用
Blood. 2009 Sep 3;114(10):2068-76. doi: 10.1182/blood-2009-03-213280. Epub 2009 May 14.
6
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.国际骨髓瘤工作组关于成像技术在多发性骨髓瘤诊断和监测中当前作用的共识声明及指南。
Leukemia. 2009 Sep;23(9):1545-56. doi: 10.1038/leu.2009.89. Epub 2009 May 7.
7
Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation.动态对比增强磁共振成像可识别出一组患有无症状单克隆浆细胞病和病理性微循环的患者。
Clin Cancer Res. 2009 May 1;15(9):3118-25. doi: 10.1158/1078-0432.CCR-08-2310. Epub 2009 Apr 14.
8
A monoclonal gammopathy precedes multiple myeloma in most patients.在大多数患者中，单克隆丙种球蛋白病先于多发性骨髓瘤出现。
Blood. 2009 May 28;113(22):5418-22. doi: 10.1182/blood-2008-12-195008. Epub 2009 Feb 20.
9
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.意义未明的单克隆丙种球蛋白病（MGUS）始终先于多发性骨髓瘤：一项前瞻性研究。
Blood. 2009 May 28;113(22):5412-7. doi: 10.1182/blood-2008-12-194241. Epub 2009 Jan 29.
10
Imaging patients with myeloma.对骨髓瘤患者进行成像检查。
Clin Radiol. 2009 Jan;64(1):1-11. doi: 10.1016/j.crad.2008.07.006. Epub 2008 Aug 29.
Zotero 插件